Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-02-07 Sale | 2024-02-09 5:43 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 29,835 | $20 | $596,805 | 299,357 (Direct) | View |
2024-02-07 Sale | 2024-02-09 5:42 pm | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 10,000 | $20.03 | $200,258 | 456,271 (Direct) | View |
2024-01-23 Sale | 2024-01-25 4:46 pm | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 90,000 | $15.78 | $1,419,759 | 166,082 (Direct) | View |
2024-01-23 Purchase | 2024-01-25 4:32 pm | Edgewise Therapeutics Inc. | EWTX | Thompson Peter A. Director 10% Owner | 454,545 | $11 | $4,999,995 | 14,756,096 (Indirect) | View |
2024-01-23 Purchase | 2024-01-25 4:28 pm | Edgewise Therapeutics Inc. | EWTX | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC Director 10% Owner | 454,545 | $11 | $4,999,995 | 14,756,096 (Indirect) | View |
2023-12-26 Purchase | 2023-12-28 4:39 pm | Edgewise Therapeutics Inc. | EWTX | Fox Jonathan C Director | 10,857 | $9.2989 | $100,958 | 10,857 (Direct) | View |
2023-12-27 Sale | 2023-12-28 4:39 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 8,497 | $10.5 | $89,219 | 0 (Direct) | View |
2023-12-26 Sale | 2023-12-28 4:38 pm | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 172,585 | $9.3293 | $1,610,097 | 3,606 (Direct) | View |
2023-05-02 Sale | 2023-05-03 6:26 pm | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 1,747 | $8.9049 | $15,557 | 17,437 (Direct) | View |
2023-05-02 Sale | 2023-05-03 6:26 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 1,897 | $8.9049 | $16,893 | 16,982 (Direct) | View |
2023-05-02 Sale | 2023-05-03 6:26 pm | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 1,336 | $8.9049 | $11,897 | 26,543 (Direct) | View |
2023-05-02 Sale | 2023-05-03 6:26 pm | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 1,602 | $8.9049 | $14,266 | 186,608 (Direct) | View |
2023-05-02 Sale | 2023-05-03 6:25 pm | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 3,254 | $8.9049 | $28,977 | 30,794 (Direct) | View |
2023-05-02 Sale | 2023-05-03 6:25 pm | Edgewise Therapeutics Inc. | EWTX | KOCH KEVIN President and CEO | 3,203 | $8.9049 | $28,522 | 366,831 (Indirect Direct) | View |
2022-10-03 Sale | 2022-10-05 4:42 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $9.7579 | $46,155 | 125,997 (Direct) | View |
2022-09-16 Purchase | 2022-09-16 4:34 pm | Edgewise Therapeutics Inc. | EWTX | Thompson Peter A. Director 10% Owner | 484,496 | $10.32 | $4,999,999 | 14,301,551 (Indirect) | View |
2022-09-16 Purchase | 2022-09-16 4:31 pm | Edgewise Therapeutics Inc. | EWTX | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC Director 10% Owner | 484,496 | $10.32 | $4,999,999 | 14,301,551 (Indirect) | View |
2022-09-14 Purchase | 2022-09-16 2:35 pm | Edgewise Therapeutics Inc. | EWTX | Novo Holdings A/S 10% Owner | 484,496 | $10.32 | $4,999,999 | 6,071,703 (Direct) | View |
2022-09-06 Sale | 2022-09-08 4:16 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $10.91 | $51,598 | 130,727 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-02-07 Exercise | 2024-02-09 5:43 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 29,835 | $0 | 299,357 (Direct) | View |
2024-02-07 Exercise | 2024-02-09 5:43 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 29,835 | $1.93 | 299,357 (Direct) | View |
2024-02-07 Exercise | 2024-02-09 5:42 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 10,000 | $0 | 456,271 (Direct) | View |
2024-02-07 Exercise | 2024-02-09 5:42 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 10,000 | $1.93 | 456,271 (Direct) | View |
2024-01-23 Exercise | 2024-01-25 4:46 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 90,000 | $0 | 166,082 (Direct) | View |
2024-01-23 Exercise | 2024-01-25 4:46 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 90,000 | $1.93 | 166,082 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 220,000 | $0 | 220,000 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 200,000 | $0 | 200,000 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 200,000 | $0 | 200,000 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 200,000 | $0 | 200,000 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | Semigran Marc Chief Development Officer | 133,333 | $0 | 133,333 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:13 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 200,000 | $0 | 200,000 (Direct) | View |
2023-08-17 Option Award | 2023-08-18 7:12 pm | N/A 2033-08-17 | Edgewise Therapeutics Inc. | EWTX | KOCH KEVIN President and CEO | 600,000 | $0 | 600,000 (Direct) | View |
2023-06-22 Exercise | 2023-06-26 4:28 pm | N/A 2030-09-01 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 10,000 | $0 | 226,146 (Direct) | View |
2023-06-22 Exercise | 2023-06-26 4:28 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 10,000 | $0.71 | 226,146 (Direct) | View |
2023-06-12 Option Award | 2023-06-14 7:30 pm | 2024-06-12 2033-06-12 | Edgewise Therapeutics Inc. | EWTX | Fox Jonathan C Director | 22,123 | $0 | 22,123 (Direct) | View |
2023-06-12 Option Award | 2023-06-14 7:29 pm | 2024-06-12 2033-06-12 | Edgewise Therapeutics Inc. | EWTX | Thompson Peter A. Director 10% Owner | 22,123 | $0 | 22,123 (Direct) | View |
2023-06-12 Option Award | 2023-06-14 7:29 pm | 2024-06-12 2033-06-12 | Edgewise Therapeutics Inc. | EWTX | ROOT JONATHAN D Director | 22,123 | $0 | 22,123 (Direct) | View |
2023-06-12 Option Award | 2023-06-14 7:29 pm | 2024-06-12 2033-06-12 | Edgewise Therapeutics Inc. | EWTX | Edris Badreddin Director | 22,123 | $0 | 22,123 (Direct) | View |
2023-06-12 Option Award | 2023-06-14 7:29 pm | 2024-06-12 2033-06-12 | Edgewise Therapeutics Inc. | EWTX | Brege Laura Director | 22,123 | $0 | 22,123 (Direct) | View |
2023-05-01 Exercise | 2023-05-03 6:26 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 5,208 | $0 | 17,437 (Direct) | View |
2023-05-01 Exercise | 2023-05-03 6:26 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 5,208 | $0 | 16,982 (Direct) | View |
2023-05-01 Exercise | 2023-05-03 6:26 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 5,208 | $0 | 26,543 (Direct) | View |
2023-05-01 Exercise | 2023-05-03 6:26 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 5,208 | $0 | 186,608 (Direct) | View |
2023-05-01 Exercise | 2023-05-03 6:25 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 10,416 | $0 | 30,794 (Direct) | View |
2023-05-01 Exercise | 2023-05-03 6:25 pm | N/A 2032-05-01 | Edgewise Therapeutics Inc. | EWTX | KOCH KEVIN President and CEO | 10,416 | $0 | 366,831 (Direct) | View |
2023-03-03 Option Award | 2023-03-07 5:59 pm | N/A 2033-03-03 | Edgewise Therapeutics Inc. | EWTX | Fox Jonathan C Director | 43,731 | $0 | 43,731 (Direct) | View |
2022-12-30 Option Award | 2023-01-03 4:44 pm | N/A 2032-12-30 | Edgewise Therapeutics Inc. | EWTX | Semigran Marc Chief Development Officer | 300,000 | $0 | 300,000 (Direct) | View |
2022-10-03 Exercise | 2022-10-05 4:42 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $0 | 125,997 (Direct) | View |
2022-10-03 Exercise | 2022-10-05 4:42 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $1.93 | 125,997 (Direct) | View |
2022-09-06 Exercise | 2022-09-08 4:16 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $0 | 130,727 (Direct) | View |
2022-09-06 Exercise | 2022-09-08 4:16 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $1.93 | 130,727 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:43 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 200,000 | $0 | 200,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:42 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 220,000 | $0 | 220,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:42 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 200,000 | $0 | 200,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:42 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 200,000 | $0 | 200,000 (Direct) | View |